The U.S. FDA approved Regeneron's garetosmab-grts (brand name Pasatru) on August 20, 2026, for treating a rare genetic bone disorder. The monoclonal antibody significantly reduced abnormal bone formation and became the second approved treatment for the condition.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
US FDA approves Regeneron's rare bone disorder drug Reuters
The #FDA has officially granted approval for #Regeneron's garetosmab-grts, to be sold under the brand name #Pasatru. A #monoclonalanitbody, it is the second treatment to be approved for the ultra-rare disease #fibrodysplasiaossificansprogressiva (FOP). pharmaphorum.com/news/fda-gre...
share.google/iz57L4CAsCvg... The U.S. FDA on Wednesday approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues.